Safety and Efficacy of Axon Therapy for Treatment of Neuropathic Pain

Background: Many of the current treatments for chronic neuropathic pain have variable effectiveness and known side effects. Given the prevalence of this type of intractable pain (3-17% of general population), additional therapeutic non-invasive approaches are desired. Magnetic Peripheral Nerve Stimu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of pain research 2024-09, Vol.17, p.3167
Hauptverfasser: Kapural, Leonardo, Patel, Janus, Rosenberg, Jason Charles, Li, Sean, Amirdelfan, Kasra, Bedder, Marshall
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page 3167
container_title Journal of pain research
container_volume 17
creator Kapural, Leonardo
Patel, Janus
Rosenberg, Jason Charles
Li, Sean
Amirdelfan, Kasra
Bedder, Marshall
description Background: Many of the current treatments for chronic neuropathic pain have variable effectiveness and known side effects. Given the prevalence of this type of intractable pain (3-17% of general population), additional therapeutic non-invasive approaches are desired. Magnetic Peripheral Nerve Stimulation (mPNS) delivered at 0.5Hz provides an effective pain relief without side effects. The objective of this randomized, controlled, multi-site clinical trial was to compare long-term safety and efficacy of mPNS in patients with chronic, intractable, post-traumatic or post-surgical neuropathic pain to comprehensive Conventional Medical Management (CMM). Methods: A total of 65 patients with post-traumatic, post-surgical neuropathy were treated within a multicenter, randomized, clinical trial comparing the safety and effectiveness of mPNS + CMM to CMM alone. Patients were randomized 1:1 and followed through 90 days. The primary endpoint is a proportion of responders, 50% or greater reduction in pain at Day 90. The secondary endpoints included the European Quality of Life 5 Dimensions 3 Level (EQ-5D-3L) and Patient Global Impression of Change (PGIC). Results: At 3 months, 71% of subjects were considered responders (>50% pain relief) in the mPNS + CMM group vs 13% of subjects in the CMM group. The mPNS + CMM group had a mean reduction in VAS scores at Day 90 of 3.8 points (>50% reduction), while CMM showed less than a 1-point (0.7 point) mean reduction or ~10% reduction (p < 0.0001). The EQ-5D-3L score increased in the mPNS + CMM study group, whereas the CMM group showed no improvement in EQ-5D-3L at Day 90. PGIC responder rates were 80.6% and 4.3% at Day 90 for mPNS + CMM and CMM groups, respectively. Conclusion: mPNS + CMM was superior to CMM in a randomized prospective study when used for treatment of post-traumatic, post-surgical neuropathy. Due to the lack of other effective non-invasive treatments for neuropathic pain, mPNS should be considered much earlier in the treatment algorithm. Keywords: neuropathic pain, noninvasive, cost effective, pain relief, neuropathy
doi_str_mv 10.2147/JPR.S481944
format Article
fullrecord <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_infotracmisc_A813513405</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A813513405</galeid><sourcerecordid>A813513405</sourcerecordid><originalsourceid>FETCH-LOGICAL-g675-b8dbb0cb7d351bcdd93761a67c19e3da07e00d0aeb65108b8e2d458bbab4b5073</originalsourceid><addsrcrecordid>eNptTMtKw0AUHUTBWl35AwOuE-8kk8xkGUp8UbTY7MudmTvtSJOUJIL9eyO66ELO4hzOi7FbAXEipLp_Wb3Ha6lFIeUZmwmhdKSggPMTfcmuhuEDINdJIWasWqOn8cixdbzyPli0R955Xn51La931OPhyH3X87onHBtqx5_0lT777oDjLli-wtBeswuP-4Fu_njO6oeqXjxFy7fH50W5jLa5yiKjnTFgjXJpJox1rkhVLjBXVhSUOgRFAA6QTJ4J0EZT4mSmjUEjTQYqnbO739st7mkTWt-NPdomDHZTajGdphKyqRX_05rgqAm2a8mHyT8ZfANU-Vtx</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Safety and Efficacy of Axon Therapy for Treatment of Neuropathic Pain</title><source>Taylor &amp; Francis Open Access</source><source>DOVE Medical Press Journals</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Kapural, Leonardo ; Patel, Janus ; Rosenberg, Jason Charles ; Li, Sean ; Amirdelfan, Kasra ; Bedder, Marshall</creator><creatorcontrib>Kapural, Leonardo ; Patel, Janus ; Rosenberg, Jason Charles ; Li, Sean ; Amirdelfan, Kasra ; Bedder, Marshall</creatorcontrib><description>Background: Many of the current treatments for chronic neuropathic pain have variable effectiveness and known side effects. Given the prevalence of this type of intractable pain (3-17% of general population), additional therapeutic non-invasive approaches are desired. Magnetic Peripheral Nerve Stimulation (mPNS) delivered at 0.5Hz provides an effective pain relief without side effects. The objective of this randomized, controlled, multi-site clinical trial was to compare long-term safety and efficacy of mPNS in patients with chronic, intractable, post-traumatic or post-surgical neuropathic pain to comprehensive Conventional Medical Management (CMM). Methods: A total of 65 patients with post-traumatic, post-surgical neuropathy were treated within a multicenter, randomized, clinical trial comparing the safety and effectiveness of mPNS + CMM to CMM alone. Patients were randomized 1:1 and followed through 90 days. The primary endpoint is a proportion of responders, 50% or greater reduction in pain at Day 90. The secondary endpoints included the European Quality of Life 5 Dimensions 3 Level (EQ-5D-3L) and Patient Global Impression of Change (PGIC). Results: At 3 months, 71% of subjects were considered responders (&gt;50% pain relief) in the mPNS + CMM group vs 13% of subjects in the CMM group. The mPNS + CMM group had a mean reduction in VAS scores at Day 90 of 3.8 points (&gt;50% reduction), while CMM showed less than a 1-point (0.7 point) mean reduction or ~10% reduction (p &lt; 0.0001). The EQ-5D-3L score increased in the mPNS + CMM study group, whereas the CMM group showed no improvement in EQ-5D-3L at Day 90. PGIC responder rates were 80.6% and 4.3% at Day 90 for mPNS + CMM and CMM groups, respectively. Conclusion: mPNS + CMM was superior to CMM in a randomized prospective study when used for treatment of post-traumatic, post-surgical neuropathy. Due to the lack of other effective non-invasive treatments for neuropathic pain, mPNS should be considered much earlier in the treatment algorithm. Keywords: neuropathic pain, noninvasive, cost effective, pain relief, neuropathy</description><identifier>ISSN: 1178-7090</identifier><identifier>EISSN: 1178-7090</identifier><identifier>DOI: 10.2147/JPR.S481944</identifier><language>eng</language><publisher>Dove Medical Press Limited</publisher><subject>Care and treatment ; Health aspects ; Medical equipment and supplies industry ; Medical test kit industry ; Pain</subject><ispartof>Journal of pain research, 2024-09, Vol.17, p.3167</ispartof><rights>COPYRIGHT 2024 Dove Medical Press Limited</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,860,27901,27902</link.rule.ids></links><search><creatorcontrib>Kapural, Leonardo</creatorcontrib><creatorcontrib>Patel, Janus</creatorcontrib><creatorcontrib>Rosenberg, Jason Charles</creatorcontrib><creatorcontrib>Li, Sean</creatorcontrib><creatorcontrib>Amirdelfan, Kasra</creatorcontrib><creatorcontrib>Bedder, Marshall</creatorcontrib><title>Safety and Efficacy of Axon Therapy for Treatment of Neuropathic Pain</title><title>Journal of pain research</title><description>Background: Many of the current treatments for chronic neuropathic pain have variable effectiveness and known side effects. Given the prevalence of this type of intractable pain (3-17% of general population), additional therapeutic non-invasive approaches are desired. Magnetic Peripheral Nerve Stimulation (mPNS) delivered at 0.5Hz provides an effective pain relief without side effects. The objective of this randomized, controlled, multi-site clinical trial was to compare long-term safety and efficacy of mPNS in patients with chronic, intractable, post-traumatic or post-surgical neuropathic pain to comprehensive Conventional Medical Management (CMM). Methods: A total of 65 patients with post-traumatic, post-surgical neuropathy were treated within a multicenter, randomized, clinical trial comparing the safety and effectiveness of mPNS + CMM to CMM alone. Patients were randomized 1:1 and followed through 90 days. The primary endpoint is a proportion of responders, 50% or greater reduction in pain at Day 90. The secondary endpoints included the European Quality of Life 5 Dimensions 3 Level (EQ-5D-3L) and Patient Global Impression of Change (PGIC). Results: At 3 months, 71% of subjects were considered responders (&gt;50% pain relief) in the mPNS + CMM group vs 13% of subjects in the CMM group. The mPNS + CMM group had a mean reduction in VAS scores at Day 90 of 3.8 points (&gt;50% reduction), while CMM showed less than a 1-point (0.7 point) mean reduction or ~10% reduction (p &lt; 0.0001). The EQ-5D-3L score increased in the mPNS + CMM study group, whereas the CMM group showed no improvement in EQ-5D-3L at Day 90. PGIC responder rates were 80.6% and 4.3% at Day 90 for mPNS + CMM and CMM groups, respectively. Conclusion: mPNS + CMM was superior to CMM in a randomized prospective study when used for treatment of post-traumatic, post-surgical neuropathy. Due to the lack of other effective non-invasive treatments for neuropathic pain, mPNS should be considered much earlier in the treatment algorithm. Keywords: neuropathic pain, noninvasive, cost effective, pain relief, neuropathy</description><subject>Care and treatment</subject><subject>Health aspects</subject><subject>Medical equipment and supplies industry</subject><subject>Medical test kit industry</subject><subject>Pain</subject><issn>1178-7090</issn><issn>1178-7090</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNptTMtKw0AUHUTBWl35AwOuE-8kk8xkGUp8UbTY7MudmTvtSJOUJIL9eyO66ELO4hzOi7FbAXEipLp_Wb3Ha6lFIeUZmwmhdKSggPMTfcmuhuEDINdJIWasWqOn8cixdbzyPli0R955Xn51La931OPhyH3X87onHBtqx5_0lT777oDjLli-wtBeswuP-4Fu_njO6oeqXjxFy7fH50W5jLa5yiKjnTFgjXJpJox1rkhVLjBXVhSUOgRFAA6QTJ4J0EZT4mSmjUEjTQYqnbO739st7mkTWt-NPdomDHZTajGdphKyqRX_05rgqAm2a8mHyT8ZfANU-Vtx</recordid><startdate>20240930</startdate><enddate>20240930</enddate><creator>Kapural, Leonardo</creator><creator>Patel, Janus</creator><creator>Rosenberg, Jason Charles</creator><creator>Li, Sean</creator><creator>Amirdelfan, Kasra</creator><creator>Bedder, Marshall</creator><general>Dove Medical Press Limited</general><scope/></search><sort><creationdate>20240930</creationdate><title>Safety and Efficacy of Axon Therapy for Treatment of Neuropathic Pain</title><author>Kapural, Leonardo ; Patel, Janus ; Rosenberg, Jason Charles ; Li, Sean ; Amirdelfan, Kasra ; Bedder, Marshall</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g675-b8dbb0cb7d351bcdd93761a67c19e3da07e00d0aeb65108b8e2d458bbab4b5073</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Care and treatment</topic><topic>Health aspects</topic><topic>Medical equipment and supplies industry</topic><topic>Medical test kit industry</topic><topic>Pain</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kapural, Leonardo</creatorcontrib><creatorcontrib>Patel, Janus</creatorcontrib><creatorcontrib>Rosenberg, Jason Charles</creatorcontrib><creatorcontrib>Li, Sean</creatorcontrib><creatorcontrib>Amirdelfan, Kasra</creatorcontrib><creatorcontrib>Bedder, Marshall</creatorcontrib><jtitle>Journal of pain research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kapural, Leonardo</au><au>Patel, Janus</au><au>Rosenberg, Jason Charles</au><au>Li, Sean</au><au>Amirdelfan, Kasra</au><au>Bedder, Marshall</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety and Efficacy of Axon Therapy for Treatment of Neuropathic Pain</atitle><jtitle>Journal of pain research</jtitle><date>2024-09-30</date><risdate>2024</risdate><volume>17</volume><spage>3167</spage><pages>3167-</pages><issn>1178-7090</issn><eissn>1178-7090</eissn><abstract>Background: Many of the current treatments for chronic neuropathic pain have variable effectiveness and known side effects. Given the prevalence of this type of intractable pain (3-17% of general population), additional therapeutic non-invasive approaches are desired. Magnetic Peripheral Nerve Stimulation (mPNS) delivered at 0.5Hz provides an effective pain relief without side effects. The objective of this randomized, controlled, multi-site clinical trial was to compare long-term safety and efficacy of mPNS in patients with chronic, intractable, post-traumatic or post-surgical neuropathic pain to comprehensive Conventional Medical Management (CMM). Methods: A total of 65 patients with post-traumatic, post-surgical neuropathy were treated within a multicenter, randomized, clinical trial comparing the safety and effectiveness of mPNS + CMM to CMM alone. Patients were randomized 1:1 and followed through 90 days. The primary endpoint is a proportion of responders, 50% or greater reduction in pain at Day 90. The secondary endpoints included the European Quality of Life 5 Dimensions 3 Level (EQ-5D-3L) and Patient Global Impression of Change (PGIC). Results: At 3 months, 71% of subjects were considered responders (&gt;50% pain relief) in the mPNS + CMM group vs 13% of subjects in the CMM group. The mPNS + CMM group had a mean reduction in VAS scores at Day 90 of 3.8 points (&gt;50% reduction), while CMM showed less than a 1-point (0.7 point) mean reduction or ~10% reduction (p &lt; 0.0001). The EQ-5D-3L score increased in the mPNS + CMM study group, whereas the CMM group showed no improvement in EQ-5D-3L at Day 90. PGIC responder rates were 80.6% and 4.3% at Day 90 for mPNS + CMM and CMM groups, respectively. Conclusion: mPNS + CMM was superior to CMM in a randomized prospective study when used for treatment of post-traumatic, post-surgical neuropathy. Due to the lack of other effective non-invasive treatments for neuropathic pain, mPNS should be considered much earlier in the treatment algorithm. Keywords: neuropathic pain, noninvasive, cost effective, pain relief, neuropathy</abstract><pub>Dove Medical Press Limited</pub><doi>10.2147/JPR.S481944</doi></addata></record>
fulltext fulltext
identifier ISSN: 1178-7090
ispartof Journal of pain research, 2024-09, Vol.17, p.3167
issn 1178-7090
1178-7090
language eng
recordid cdi_gale_infotracmisc_A813513405
source Taylor & Francis Open Access; DOVE Medical Press Journals; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; PubMed Central Open Access
subjects Care and treatment
Health aspects
Medical equipment and supplies industry
Medical test kit industry
Pain
title Safety and Efficacy of Axon Therapy for Treatment of Neuropathic Pain
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T07%3A20%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20and%20Efficacy%20of%20Axon%20Therapy%20for%20Treatment%20of%20Neuropathic%20Pain&rft.jtitle=Journal%20of%20pain%20research&rft.au=Kapural,%20Leonardo&rft.date=2024-09-30&rft.volume=17&rft.spage=3167&rft.pages=3167-&rft.issn=1178-7090&rft.eissn=1178-7090&rft_id=info:doi/10.2147/JPR.S481944&rft_dat=%3Cgale%3EA813513405%3C/gale%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A813513405&rfr_iscdi=true